Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu- CC49: A phase I/II study

Gynecologic Oncology

Volumn 65, Issue 1, 1997, Pages 94-101

  Alvarez, Ronald D ^a   Partridge, Edward E ^a   Khazaeli, M B ^b   Plott, Gene ^e   Austin, Max ^a   Kilgore, Larry ^a   Russell, Charles D ^a   Liu, Tiepu ^b   Grizzle, William E ^c   Schlom, Jeffrey ^f   LoBuglio, Albert F ^g   Meredith, Ruby F ^d  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

^c University of Alabama at Birmingham   (United States)

^d The University of Alabama at Birmingham   (United States)

^e DCH Cancer Treatment Center   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

LANTHANIDE; MONOCLONAL ANTIBODY CC49; RADIOISOTOPE;

ADULT; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DOSIMETRY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; INTRAPERITONEAL DRUG ADMINISTRATION; ISOTOPE LABELING; LYMPH NODE METASTASIS; OCCULT CANCER; OVARY CANCER; PARAAORTIC LYMPH NODE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY;

EID: 0031127626     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1996.4577     Document Type: Article

References (36)

1. 1. Venesmaa P: Epithelial ovarian cancer: Impact of surgery and chemotherapy on survival during 1977-1990. Obstet Gynecol 84:8-11, 1994
2. 2. Epenetos AA, Munro AJ, Stewart S, Rampling R, Lambert HE, McKenzie CG, Soutter P, Rahemtulla A, Hooker G, Sivolapenko GB: Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies. J Clin Oncol 5:1890-1899, 1987
3. 3. Fein DA, Morgan LS, Marcus RB, Jr, Mendenhall WM, Sombeck MD, Freeman DE, Million RR: Stage III ovarian carcinoma: An analysis of treatment results and complications following hyperfractionated abdominopelvic irradiation for salvage. Int J Radiat Oncol Biol Phys 29:169-176, 1994
4. 4. Hird V, Maraveyas A, Snook D, Dhokia B, Soutter WP, Meares C, Stewart JS, Mason P, Lambert HE, Epenetos AA: Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br J Cancer 68:403-406, 1993
5. 90Y with and without EDTA in ovarian cancer, in Proceedings, Advances in Innovative Oncology: Biomodulation, Chemoimmunotherapy and Selected Phase II Drugs, 1991, pp 38-40
6. 6. Markman M, Rowinsky E, Hakes T, Reichman B, Jones W, Lewis JL, Jr, Rubin S, Curtin J, Barakat R, Phillips M: Phase I trial of intraperitoneal taxol: A Gynecologic Oncology Group study. J Clin Oncol 10:1485-1491, 1992
7. 7. Markman M, Reichman B, Hakes T, Curtin J, Jones W, Lewis JL, Jr, Barakat R, Rubin S, Mychalczak B, Saigo P: Intraperitoneal chemotherapy in the management of ovarian cancer (Review). Cancer 71(4, Suppl.): 1565-1570, 1993
8. 8. Muto MG, Finkler NJ, Kassis AI, Howes AE, Anderson LL, Lau CC, Zurawski VR, Jr, Weadock K, Tumeh SS, Lavin P: Intraperitoneal radioimmunotherapy of refractory ovarian carcinoma utilizing iodine-131-labeled monoclonal antibody OC125. Gynecol Oncol 45:265-272, 1992
9. 9. Piver M, Recio F, Baker T, Driscoll D: Evaluation of survival after second-line intraperitoneal cisplatin-based chemotherapy for advanced ovarian cancer. Cancer 73:1693-1698, 1994
10. 10. Jacobs AJ, Fer M, Su FM, Breitz H, Thompson J, Goodgold H, Cain M, Heaps J, Weiden P: A phase I trial of a rhenium 186-labeled monoclonal antibody administered intraperitoneally in ovarian carcinoma: Toxicity and clinical response. Obstet Gynecol 82:586-593, 1993
11. 90Y-labeled monoclonal antibodies for ovarian cancer: Pharmacokinetics and normal tissue dosimetry. Int J Cancer 3:S71-S76, 1988
12. 131I-labeled B72.3 monoclonal antibody. Radiology 167:35-40, 1988
13. 13. Larson SM, Carrasquillo JA, Colcher DC, Yokoyama K, Reynolds JC, Bacharach SA, Raubitchek A, Pace L, Finn RD, Rotman M: Estimates of radiation absorbed dose for intraperitoneally administered iodine-131 radiolabeled B72.3 monoclonal antibody in patients with peritoneal carcinomatoses. J Nucl Med 32:1661-1667, 1991
14. 14. Chatal JF, Saccavini JC, Gestin JF, Thedrez P, Curtet C, Kremer M, Guerreau D, Nolibe D, Fumoleau P, Guillard Y: Biodistribution of indium-111-labeled OC 125 monoclonal antibody intraperitoneally injected into patients operated on for ovarian carcinomas. Cancer Res 49:3087-3094, 1989
15. 15. Colcher D, Esteban J, Carrasquillo J: Complementation of intracavitary and intravenous administration of a monoclonal antibody B72.3 in patients with carcinoma. Cancer Res 47:4218-4224, 1987
16. 16. Ward BG, Mather SJ, Hawkins LR, Crowther ME, Shepherd JH, Granowska M, Britton KE, Slevin ML: Localization of radioiodine conjugated to the monoclonal antibody HMFG2 in human ovarian carcinoma: Assessment of intravenous and intraperitoneal routes of administration. Cancer Res 47:4719-4723, 1987
17. 17. Schlom J, Colcher D, Siler K, Thor A, Bryant G, Johnston WW, Szpak CA, Sugarbaker P, Carrasquillo JA, Reynolds JC: Tumor targeting with monoclonal antibody B72.3: Experimental and clinical results (Review). Cancer Treat Res 51:313-335, 1990
18. 18. Divgi CR, Scott AM, Dantis L, Capitelli P, Siler K, Hilton S, Finn RD, Kemeny N, Kelsen D, Kostakoglu L: Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma. J Nucl Med 36:586-592, 1995
19. 19. Meredith RF, Bueschen AJ, Khazaeli MB, Plott WE, Grizzle WE, Wheeler RH, Schlom J, Russell CD, Liu T, LoBuglio AF: Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. J Nucl Med 35:1017-1022, 1994
20. 131I-CC49 murine MAB plus alpha interferon in refractory breast cancer (Abstract). Antib Immunoconj Radiopharm 7:84, 1994
21. 21. Schlom J, Eggensperger D, Colcher D, Molinolo A, Houchens D, Miller LS, Hinkle G, Siler K: Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates. Cancer Res 52:1067-1072, 1992
22. 22. Colcher D, Minelli MF, Roselli M, Muraro R, Simpson-Milenic D, Schlom J: Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies. Cancer Res 48:4597-4603, 1988
23. 23. Gallinger S, Reilly RM, Kirsh JC, Odze RD, Schmocker BJ, Hay K, Polihronis J, Damani MT, Shpitz B, Stern HS: Comparative dual label study of first and second generation antitumor-associated glycoprotein-72 monoclonal antibodies in colorectal cancer patients. Cancer Res 53:271-278, 1993
24. 177lutetium-labeled immunoconjugate. Cancer Res 51:2889-2896, 1991
25. 177Lu-CC49. J Nucl Med 37:1491-1496, 1996
26. 26. Meredith RF, LoBuglio AF, Plott WE, Orr RA, Brezovich IA, Russell CD, Harvey EB, Yester MV, Wagner AJ, Spencer SA, Wheeler RH, Saleh MN, Rogers KJ, Polansky A, Salter MM, Khazaeli MB: Pharmacokinetics, immune response, and biodistribution of iodine-131-labeled chimeric mouse/human IgG1,k 17-1A monoclonal antibody. J Nucl Med 32:1162-1168, 1991
27. 27. Loevinger R, Berman A: A Revised Schema for Calculating the Absorbed Dose from Biologically Distributed Radionuclides, MIRD Pamphlet No. 1 (revised with foreword by R. J. Cloutier and E. M. Smith), New York, Society of Nuclear Medicine, 1976
28. 177Lu-CC49 (Abstract), in Sixth International Radiopharmaceutical Dosimetry Symposium, Gatlinburg, TN, May 1996
29. 29. Khazaeli MB: Quantitation of mouse monoclonal antibody and human anti-mouse antibody response in serum of patients. Hybridoma 8:231-239, 1989
30. 30. Labaune JP: Handbook of Pharmacokinetics, Toxicity Assessment of Chemicals, New York, Wiley, 1989
31. 31. Liu T: Characteristics of pharmacokinetical modeling in phase I clinical trial of radiolabeled monoclonal antibody chimeric B72.3. Controlled Clin Trials 12:654-655, 1991
32. 177Lu-CC49 monoclonal antibody in patients with recurrent or persistent ovarian cancer (Abstract), in Advances in the Application of Monoclonal Antibodies in Clinical Oncology. Eleventh International Hammersmith Conference, Molyvos, Lesvos, Greece, May 23-26, 1994
33. 33. Vergote IB, Vergote-De Vos LN, Abeler VM, Aas M, Lindegaard MW, Kjorstad KE, Trope CG: Randomized trial comparing cisplatin with radioactive phosphorus or whole-abdomen irradiation as adjuvant treatment of ovarian cancer. Cancer 69:741-749, 1992
34. 177Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma. Clin Cancer Res 1:1447-1454, 1995
35. 35. Pattillo RA, Collier BD, Abdel-Dayem H, Ozker K, Wilson C, Ruckert AC, Hamilton K: Phosphorus-32-chromic phosphate for ovarian cancer: I. Fractionated low-dose intraperitoneal treatments in conjunction with platinum analog chemotherapy. J Nucl Med 36:29-36, 1995
36. 36. Rowlinson G, Snook D, Busza A, Epenetos AA: Antibody-guided localization of intraperitoneal tumors following intraperitoneal or intravenous antibody administration. Cancer Res 47:6528-6531, 1987.